Zobrazeno 1 - 10
of 19 147
pro vyhledávání: ''
The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution
Autor:
Alyce A. Chen, Sandro Santagata, Yu-An Chen, Raquel Arias-Camison, Connor A. Jacobson, Christine G. Lian, Roxanne J. Pelletier, Brian Quattrochi, Peter K. Sorger, Ajit J. Nirmal, George F. Murphy, Clarence Yapp, Zoltan Maliga, Tuulia Vallius
Publikováno v:
Cancer Discov
Cutaneous melanoma is a highly immunogenic malignancy that is surgically curable at early stages but life-threatening when metastatic. Here we integrate high-plex imaging, 3D high-resolution microscopy, and spatially resolved microregion transcriptom
Autor:
Erickson A, Carlos S. Moreno, Michelle M. Kouspou, Fred Saad, Michael S. Lewis, Onur Ertunc, Adeboye O. Osunkoya, Colm Morrissey, Bigler Sa, Tuomas Mirtti, Anne-Marie Mes-Masson, Stephen J. Freedland, Zhou X, Igor Vidal, Aud Svindland, Larry True, Tracy Jones, Ouellet, Mark Buzza, Wiley K, Tasken Ka, Pekka Taimen, Isla P. Garraway, Ariel H Achtman, Bova Sg, Angelo M. De Marzo, Bruce J. Trock, Dominique Trudel, Berge, Tarja Lamminen, Beatrice S. Knudsen
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:715-727
Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Pl
Autor:
Madhavi Puchallapalli, Nicholas Farrell, Bin Hu, Mohammad A. Alzubi, Tia H. Turner, James D. Hampton, Larisa Litovchick, Vita Kraskauskiene, Samantha J. Katner, Jennifer E. Koblinski, Kazuaki Takabe, J. Chuck Harrell, Mayuri Shende, Joseph B. McGee Turner, Michael O. Idowu, Erica J. Peterson, Mikhail G. Dozmorov, Eriko Katsuta, Pamela J Gigliotti
Publikováno v:
Mol Cancer Ther
Triple-negative breast cancer (TNBC) is a subtype of breast cancer lacking targetable biomarkers. TNBC is known to be most aggressive and when metastatic is often drug-resistant and uncurable. Biomarkers predicting response to therapy improve treatme
Autor:
Dominic Edelmann, Elizabeth Alwers, Hermann Brenner, Michael Hoffmeister, Lina Jansen, Hanla A Park, Jenny Chang-Claude, Axel Benner, Martin Schneider, Federico Canzian, Petra Seibold
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:352-361
Background: Associations between candidate genetic variants and treatment outcomes of oxaliplatin, a drug commonly used for colorectal cancer patients, have been reported but not robustly established. This study aimed to validate previously reported
Autor:
J. Qiu, Umesh Bhanot, John T. Poirier, Yingqian Zhan, Elisa de Stanchina, Viola Allaj, Hirokazu Taniguchi, Fathema Uddin, Travis J. Hollmann, Jordana Ray-Kirton, Metamia Ciampricotti, Andrew Chow, Marina Asher, Richard Koche, Álvaro Quintanal-Villalonga, Jacklynn V. Egger, Yuan Hao, Joseph M. Chan, Shweta S Chavan, Charles M. Rudin, Michael H.A. Roehrl, Triparna Sen, Michael Offin, Irina Linkov, Nisargbhai S. Shah, P. Manoj
Publikováno v:
Cancer Res
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet chemotherapy, with the recent addition of
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Gregory T. Armstrong, Tatiana Goltsova, Tsz-Kwong Man, Elmira Hariri, Wanda LeJeune, Leslie L. Robison, Yutaka Yasui, Joseph P. Neglia, Smita Bhatia, Melissa A. Richard, Geraldine Aubert, Maria M. Gramatges, Amos Gaikwad, Wendy M. Leisenring, Yan Chen, J. Whitton, Michael Arnold
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: Survivors of childhood cancer are at risk for therapy-related subsequent malignant neoplasms (SMN), including thyroid SMN. Telomere length (TL) is associated with cancer risk, but the relationship between TL and SMN risk among survivors i
Publikováno v:
Cancer Research. 82:320-333
Basal-like breast cancer is the most aggressive breast cancer subtype with the worst prognosis. Despite its high recurrence rate, chemotherapy is the only treatment for basal-like breast cancer, which lacks expression of hormone receptors. In contras
Autor:
Emmy W. Verschuren, Pekka Paivinen, Sushil Tripathi, Ashwini S. Nagaraj, Eva Domenech-Moreno, Tomi P. Mäkelä, Kari Vaahtomeri, Iris P. L. Wong, Sarang S. Talwelkar, Marc Foretz, Benoit Viollet, Yan Yan, Yajing Gao
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, 2021, pp.clincanres.2049.2021. ⟨10.1158/1078-0432.CCR-21-2049⟩
Clinical Cancer Research, American Association for Cancer Research, 2021, pp.clincanres.2049.2021. ⟨10.1158/1078-0432.CCR-21-2049⟩
Clinical Cancer Research, 2021, pp.clincanres.2049.2021. ⟨10.1158/1078-0432.CCR-21-2049⟩
Clinical Cancer Research, American Association for Cancer Research, 2021, pp.clincanres.2049.2021. ⟨10.1158/1078-0432.CCR-21-2049⟩
Purpose: Mutations in STK11 (LKB1) occur in 17% of lung adenocarcinoma (LUAD) and drive a suppressive (cold) tumor immune microenvironment (TIME) and resistance to immunotherapy. The mechanisms underpinning the establishment and maintenance of a cold
Autor:
Elizabeth A Mendes, Sarah C. Van Alsten, Jeremy Force, Brock McKinney, Ashley V. DiMarco, Kouros Owzar, Jichun Xie, Nina Marie G. Garcia, Melissa A. Troester, Xiaodi Qin, Brent A. Hanks, James V. Alvarez
Publikováno v:
Cancer Immunol Res
The APOBEC family of cytidine deaminases is one of the most common endogenous sources of mutations in human cancer. Genomic studies of tumors have found that APOBEC mutational signatures are enriched in the HER2 subtype of breast cancer and are assoc